Drugs / BLKR201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07501039 | Apr 2026 → Feb 2027 expected | — | Formation Bio, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Formation Bio, Inc. | Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor formation.bio ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLKR201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07501039 ↗ |
| Route | Oral | “BLKR201 is administered orally once daily for 7 consecutive days in the MAD stage.” NCT07501039 ↗ |